Your browser doesn't support javascript.
loading
Radiobiological and dosimetric comparison of 60Co versus 192Ir high-dose-rate intracavitary-interstitial brachytherapy for cervical cancer.
Wen, Aiping; Wang, Xianliang; Wang, Bingjie; Yan, Chuanjun; Luo, Jingyue; Wang, Pei; Li, Jie.
Afiliación
  • Wen A; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
  • Wang X; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, 610041, China.
  • Wang B; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
  • Yan C; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, 610041, China.
  • Luo J; Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hongkong, 999077, China.
  • Wang P; Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
  • Li J; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Radiat Oncol ; 17(1): 206, 2022 Dec 13.
Article en En | MEDLINE | ID: mdl-36514118
BACKGROUND: High-dose-rate (HDR) intracavitary-interstitial brachytherapy (IC-ISBT) is an effective treatment for bulky, middle, and advanced cervical cancer. In this study, we compared the differences between 60Co and 192Ir HDR IC-ISBT plans in terms of radiobiological and dosimetric parameters, providing a reference for clinical workers in brachytherapy. METHODS: A total of 30 patients with cervical cancer receiving HDR IC-ISBT were included in this study, and IC-ISBT plans for each individual were designed with both 60Co and 192Ir at a prescribed dose of CTV D90 = 6 Gy while keeping the dose to OARs as low as possible. Physical dose and dose-volume parameters of CTV and OARs were extracted from TPS. The EQD2, EUBED, EUD, TCP, and NTCP were calculated using corresponding formulas. The differences between the 60Co and 192Ir IC-ISBT plans were compared using the paired t-test. RESULTS: In each patient's 60Co and 192Ir IC-ISBT plan, the average physical dose and EQD2 of 60Co were lower than those of 192Ir, and there were statistically significant differences in D2cc and D1cc for the OARs (p < 0.05); there were statistically significant differences in D0.1 cc for the bladder (p < 0.05) and no significant differences in D0.1 cc for the rectum or intestines (p > 0.05). The EUBED ratio (60Co/192Ir) at the CTV was mostly close to 1 when neither 60Co or 192Ir passed their half-lives or when both passed two half-lives, and the difference between them was not significant; at the OARs, the mean value of 60Co was lower than that of 192Ir. There was no statistical difference between 60Co and 192Ir in the EUD (93.93 versus 93.92 Gy, p > 0.05) and TCP (97.07% versus 97.08%, p > 0.05) of the tumors. The mean NTCP value of 60Co was lower than that of 192Ir. CONCLUSIONS: Considering the CTV and OARs, the dosimetric parameters of 60Co and 192Ir are comparable. Compared with 192Ir, the use of 60Co for HDR IC-ISBT can ensure a similar tumor control probability while providing better protection to the OARs. In addition, 60Co has obvious economic advantages and can be promoted as a good alternative to 192Ir.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Braquiterapia / Neoplasias del Cuello Uterino Tipo de estudio: Etiology_studies Límite: Female / Humans Idioma: En Revista: Radiat Oncol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Braquiterapia / Neoplasias del Cuello Uterino Tipo de estudio: Etiology_studies Límite: Female / Humans Idioma: En Revista: Radiat Oncol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido